

![]() |
Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030 |
|
Authors | ![]() | |
Published in | Swiss Medical Weekly. 2017, vol. 147, w14543 | |
Abstract | In Switzerland, the prevalence of hepatitis C virus (HCV) among people who inject drugs (PWID) has been decreasing owing to active harm reduction efforts and an aging population. Recent advances in HCV therapeutics may provide an opportunity to direct treatment to high-risk populations, with a goal of reducing HCV prevalence and preventing new infections. In order to guide these efforts, the current project was undertaken with the following aims: (1) to develop a simple model to estimate the number of new HCV infections using available data on PWID; (2) to examine the impact of intervention strategies (prevention and treatment) on new and total HCV infections among PWID. | |
Identifiers | PMID: 29120012 | |
Full text | ||
Structures | ||
Research group | Etudes et traitement de l'hépatite C et B (554) | |
Citation (ISO format) | BRUGGMANN, Philip et al. Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. In: Swiss Medical Weekly, 2017, vol. 147, p. w14543. doi: 10.4414/smw.2017.14543 https://archive-ouverte.unige.ch/unige:106613 |